FMP
Tiziana Life Sciences Ltd
TLSA
NASDAQ
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
0.841 USD
0.051 (6.06%)
About
ceo
Mr. Gabriele Marco Antonio Cerrone M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.tizianalifesciences.com
exchange
NASDAQ
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL...
CIK
0001723069
ISIN
BMG889121031
CUSIP
88875G101
Address
55 Park Lane
Phone
44 20 7495 2379
Country
GB
Employee
9
IPO Date
Nov 20, 2018
Summary
CIK
0001723069
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
88875G101
ISIN
BMG889121031
Country
GB
Price
0.84
Beta
0.5
Volume Avg.
155.7k
Market Cap
84.61M
Shares
-
52-Week
0.41-1.27
DCF
0.22
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-5.61
P/B
-
Website
https://www.tizianalifesciences.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TLSA News
It looks like there's no news available.
